[go: up one dir, main page]

FI3406609T3 - Bicyclic aza compounds as muscarinic receptor agonists - Google Patents

Bicyclic aza compounds as muscarinic receptor agonists Download PDF

Info

Publication number
FI3406609T3
FI3406609T3 FIEP18179258.1T FI18179258T FI3406609T3 FI 3406609 T3 FI3406609 T3 FI 3406609T3 FI 18179258 T FI18179258 T FI 18179258T FI 3406609 T3 FI3406609 T3 FI 3406609T3
Authority
FI
Finland
Prior art keywords
compound
salt
treatment
salt according
receptor agonists
Prior art date
Application number
FIEP18179258.1T
Other languages
Finnish (fi)
Inventor
Giles Albert Brown
Julie Elaine Cansfield
Miles Stuart Congreve
Michael Alistair O'brien
Mark Pickworth
Mark David Rackham
Benjamin Gerald Tehan
Barry John Teobald
Original Assignee
Nxera Pharma Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52465550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI3406609(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1402013.5A external-priority patent/GB201402013D0/en
Priority claimed from GBGB1416622.7A external-priority patent/GB201416622D0/en
Application filed by Nxera Pharma Uk Ltd filed Critical Nxera Pharma Uk Ltd
Application granted granted Critical
Publication of FI3406609T3 publication Critical patent/FI3406609T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)

Claims (10)

EP3406609 1 PatenttivaatimuksetEP3406609 1 Patent claims 1. Yhdiste, joka on etyyli-2-[4-(1-metyyli-1H-pyratsol-5-yyli)piperidin-1-yyli]-6- atsaspiro[3.4]oktaani-6-karboksylaatti tai sen suola.1. A compound which is ethyl 2-[4-(1-methyl-1H-pyrazol-5-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate or a salt thereof. 2. Patenttivaatimuksen 1 mukaisen yhdisteen farmaseuttisesti hyväksyttävä suola.2. A pharmaceutically acceptable salt of the compound according to claim 1. 3. Patenttivaatimuksen 1 mukaisen yhdisteen happoadditiosuola.3. Acid addition salt of the compound according to claim 1. 4. Patenttivaatimuksen 3 mukainen happoadditiosuola, jossa happo on — sittuunahappo, fumaarihappo tai suolahappo.4. An acid addition salt according to claim 3, wherein the acid is — citric acid, fumaric acid or hydrochloric acid. 5. Lääkekoostumus, joka käsittää jonkin patenttivaatimuksen 1-4 mukaista yhdistettä tai suolaa ja farmaseuttisesti hyväksyttävää apuainetta.5. A pharmaceutical composition comprising a compound or salt according to one of claims 1-4 and a pharmaceutically acceptable excipient. — 6. Jonkin patenttivaatimuksen 1-4 mukainen yhdiste tai suola käytettäväksi Alzheimerin taudin hoidossa.— 6. A compound or salt according to one of claims 1-4 for use in the treatment of Alzheimer's disease. 7. Jonkin patenttivaatimuksen 1-4 mukainen yhdiste tai suola käytettäväksi skitsofrenian hoidossa.7. A compound or salt according to one of claims 1-4 for use in the treatment of schizophrenia. 8. Jonkin patenttivaatimuksen 1-4 mukainen yhdiste tai suola käytettäväksi bipolaarisen häiriön hoidossa.8. A compound or salt according to one of claims 1-4 for use in the treatment of bipolar disorder. 9. Jonkin patenttivaatimuksen 1-4 mukainen yhdiste tai suola käytettäväksi dementian hoidossa.9. A compound or salt according to one of claims 1-4 for use in the treatment of dementia. 10. Jonkin patenttivaatimuksen 1-4 mukainen yhdiste tai suola käytettäväksi Lewyn kappale -taudin hoidossa.10. A compound or salt according to one of claims 1-4 for use in the treatment of Lewy body disease.
FIEP18179258.1T 2014-02-06 2015-02-06 Bicyclic aza compounds as muscarinic receptor agonists FI3406609T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1402013.5A GB201402013D0 (en) 2014-02-06 2014-02-06 Pharmaceutical compounds
GBGB1416622.7A GB201416622D0 (en) 2014-09-19 2014-09-19 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
FI3406609T3 true FI3406609T3 (en) 2024-09-10

Family

ID=52465550

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP18179258.1T FI3406609T3 (en) 2014-02-06 2015-02-06 Bicyclic aza compounds as muscarinic receptor agonists

Country Status (31)

Country Link
US (6) US9670183B2 (en)
EP (3) EP4413985A3 (en)
JP (3) JP6479029B2 (en)
KR (1) KR102352388B1 (en)
CN (2) CN106458986B (en)
AU (3) AU2015213900B2 (en)
BR (1) BR112016017979B1 (en)
CA (1) CA2938169C (en)
CL (1) CL2016001983A1 (en)
CY (1) CY1120834T1 (en)
DK (2) DK3406609T3 (en)
ES (2) ES2688548T3 (en)
FI (1) FI3406609T3 (en)
HK (1) HK1231473A1 (en)
HR (2) HRP20241145T1 (en)
HU (1) HUE068301T2 (en)
IL (1) IL247117B (en)
LT (2) LT3102568T (en)
MX (2) MX371529B (en)
NZ (1) NZ723103A (en)
PH (1) PH12016501570B1 (en)
PL (2) PL3102568T3 (en)
PT (2) PT3406609T (en)
RS (2) RS65894B1 (en)
RU (1) RU2685230C2 (en)
SA (1) SA516371614B1 (en)
SG (1) SG11201606269WA (en)
SI (2) SI3406609T1 (en)
SM (1) SMT202400446T1 (en)
UA (1) UA122121C2 (en)
WO (1) WO2015118342A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033114T2 (en) 2011-11-18 2017-11-28 Heptares Therapeutics Ltd Muscarinic m1 receptor agonists
TR201819092T4 (en) 2013-03-15 2019-01-21 Verseon Corp Multi-substituted aromatic compounds as serine protease inhibitors.
AU2015213900B2 (en) 2014-02-06 2018-12-13 Nxera Pharma Uk Limited Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
KR20170048410A (en) 2014-09-17 2017-05-08 베르선 코포레이션 Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
JP2018506563A (en) * 2015-02-27 2018-03-08 ヴァーセオン コーポレイション Substituted pyrazole compounds as serine protease inhibitors
GB201504675D0 (en) 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513742D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513740D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201519352D0 (en) * 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
ES2789756T3 (en) 2015-12-23 2020-10-26 Merck Sharp & Dohme Allosteric modulators of 6,7-dihydro-5H-pyrrolo [3,4-b] pyridin-5-one of the muscarinic acetylcholine receptor M4
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
BR112018077257A2 (en) * 2016-07-01 2019-04-02 Pfizer Inc. 5,7-dihydro-pyrrole-pyridine derivatives for the treatment of neurological and neurodegenerative diseases
GB201617454D0 (en) * 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
GB201709652D0 (en) 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
JP7134173B2 (en) 2017-06-21 2022-09-09 第一三共株式会社 EP300/CREBBP inhibitor
WO2019000237A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 3-(1h-pyrazol-4-yl)pyridine allosteric modulators of m4 muscarinic acetylcholine receptor
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5-(pyridin-3-yl)oxazole allosteric modulators of m4 muscarinic acetylcholine receptor
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 3-(1h-pyrazol-4-yl)pyridine allosteric modulators of m4 muscarinic acetylcholine receptor
US20200369611A1 (en) * 2017-08-01 2020-11-26 Boehringer Ingelheim International Gmbh Intermediate compounds and methods
US10501483B2 (en) 2017-10-24 2019-12-10 Allergan, Inc. Enamines and diastereo-selective reduction of enamines
EP3732163A4 (en) * 2017-12-20 2021-07-14 Vanderbilt University MUSCARINIAN ACETYLCHOLINE RECEPTOR ANTAGONISTS M4
TWI801540B (en) 2018-03-23 2023-05-11 美商輝瑞大藥廠 Piperazine azaspiro derivatives
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201810245D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
CU20220023A7 (en) * 2019-10-09 2022-11-07 Novartis Ag 2-AZASPIRO[3,4]OCTANE DERIVATIVES AS M4 AGONISTS
JP7349567B2 (en) * 2019-10-09 2023-09-22 ノバルティス アーゲー 5-oxa-2-azaspiro[3.4]octane derivatives as M4 agonists
US11912705B2 (en) * 2020-08-20 2024-02-27 The Corporation Of Mercer University Cathinone derivatives, pharmaceutical formulations, and methods
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
AR130114A1 (en) 2022-08-04 2024-11-06 Heptares Therapeutics Ltd MUSCARINIC RECEPTOR AGONISTS
AU2023341169A1 (en) * 2022-09-16 2025-03-13 Cerevel Therapeutics, Llc M4 activators/modulators and uses thereof
WO2024151833A1 (en) * 2023-01-12 2024-07-18 Cerevel Therapeutics, Llc Spiro derivatives as m4 activators/modulators and uses thereof
WO2024158645A1 (en) 2023-01-24 2024-08-02 Neurocrine Biosciences, Inc. Deuterated compounds
WO2025030095A1 (en) 2023-08-03 2025-02-06 Neurocrine Biosciences, Inc. Methods of synthesis

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852029A (en) 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
WO1999032489A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
JPWO2002085890A1 (en) * 2001-04-20 2004-08-12 萬有製薬株式会社 Benzimidazolone derivatives
JP2008501031A (en) * 2004-05-28 2008-01-17 バーテックス　ファーマシューティカルズ　インコーポレイテッド Muscarinic receptor modulators
EP1863490A2 (en) * 2005-03-28 2007-12-12 Vertex Pharmaceuticals Incorporated Muscarinic modulators
CA2634456A1 (en) 2005-12-22 2007-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
AU2007221214A1 (en) 2006-02-22 2007-09-07 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
KR20080098070A (en) * 2006-02-22 2008-11-06 버텍스 파마슈티칼스 인코포레이티드 Spirally condensed piperidine as modulator of muscarinic receptors
RU2008139192A (en) * 2006-03-03 2010-04-10 Новартис АГ (CH) N-FORMYL HYDROXYLAMINES
GB0706188D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
WO2010049146A1 (en) 2008-10-29 2010-05-06 Grünenthal GmbH Substituted spiroamines
FR2945531A1 (en) 2009-05-12 2010-11-19 Sanofi Aventis 7-AZA-SPIRO® 3,5-NONANE-7-CARBOXYLATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
WO2012020813A1 (en) * 2010-08-10 2012-02-16 大日本住友製薬株式会社 Fused-ring pyrrolidine derivative
HUE033114T2 (en) * 2011-11-18 2017-11-28 Heptares Therapeutics Ltd Muscarinic m1 receptor agonists
ES2602039T3 (en) * 2012-09-18 2017-02-17 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic M1 receptor agonists
EP2991980B1 (en) 2013-04-30 2019-01-02 Glaxosmithkline Intellectual Property (No. 2) Limited Enhancer of zeste homolog 2 inhibitors
TWI620755B (en) 2014-02-06 2018-04-11 里伯賽恩斯有限責任公司 4'-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication
AU2015213900B2 (en) * 2014-02-06 2018-12-13 Nxera Pharma Uk Limited Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists
US11078193B2 (en) 2014-02-06 2021-08-03 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
SG11201701915TA (en) 2014-09-19 2017-04-27 Glaxosmithkline Ip Dev Ltd Novel soluble guanylate cyclase activators and their use
US10350206B2 (en) 2014-09-19 2019-07-16 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as BUB1 inhibitors
CN107001328B (en) 2014-09-19 2020-06-05 福马治疗股份有限公司 Pyridin-2(1H)-ketoquinolinone derivatives as mutant isocitrate dehydrogenase inhibitors

Also Published As

Publication number Publication date
JP2017505323A (en) 2017-02-16
DK3102568T3 (en) 2018-10-08
HRP20241145T1 (en) 2024-11-22
JP2023073504A (en) 2023-05-25
EP3102568B1 (en) 2018-06-27
AU2020277225A1 (en) 2020-12-24
KR102352388B1 (en) 2022-01-17
DK3406609T3 (en) 2024-08-26
JP6479029B2 (en) 2019-03-06
CN109851610A (en) 2019-06-07
EP4413985A3 (en) 2024-10-23
PL3102568T3 (en) 2019-01-31
EP3406609A1 (en) 2018-11-28
EP4413985A2 (en) 2024-08-14
HRP20181499T1 (en) 2018-11-30
ES2986327T3 (en) 2024-11-11
SMT202400446T1 (en) 2024-11-15
US10196380B2 (en) 2019-02-05
NZ723103A (en) 2022-09-30
LT3102568T (en) 2018-11-12
US20200325118A1 (en) 2020-10-15
KR20160129014A (en) 2016-11-08
RS57843B1 (en) 2018-12-31
PT3102568T (en) 2018-10-24
EP3102568A1 (en) 2016-12-14
LT3406609T (en) 2024-09-25
US10689368B2 (en) 2020-06-23
BR112016017979A2 (en) 2017-08-08
CL2016001983A1 (en) 2017-06-23
US10961225B2 (en) 2021-03-30
AU2015213900A1 (en) 2016-08-11
CY1120834T1 (en) 2019-12-11
RU2016133684A (en) 2018-03-14
US10385039B2 (en) 2019-08-20
US20170240530A1 (en) 2017-08-24
BR112016017979B1 (en) 2022-08-02
PH12016501570A1 (en) 2016-10-03
SI3406609T1 (en) 2024-10-30
US9926297B2 (en) 2018-03-27
CN106458986A (en) 2017-02-22
IL247117B (en) 2021-03-25
JP6774513B2 (en) 2020-10-28
US20190337925A1 (en) 2019-11-07
CN109851610B (en) 2021-09-21
PL3406609T3 (en) 2024-11-25
JP2019077725A (en) 2019-05-23
AU2015213900B2 (en) 2018-12-13
EP3406609B1 (en) 2024-06-26
US9670183B2 (en) 2017-06-06
JP2023087045A (en) 2023-06-22
US20170015650A1 (en) 2017-01-19
SA516371614B1 (en) 2019-10-30
US20180179184A1 (en) 2018-06-28
WO2015118342A1 (en) 2015-08-13
AU2019201579B2 (en) 2020-08-27
PH12016501570B1 (en) 2016-10-03
CA2938169C (en) 2022-03-15
CA2938169A1 (en) 2015-08-13
MX371529B (en) 2020-01-31
UA122121C2 (en) 2020-09-25
HUE068301T2 (en) 2024-12-28
IL247117A0 (en) 2016-09-29
US20190112294A1 (en) 2019-04-18
MX2016010322A (en) 2017-04-27
AU2019201579A1 (en) 2019-03-28
RU2685230C2 (en) 2019-04-17
SI3102568T1 (en) 2018-11-30
MX2020001236A (en) 2022-06-30
RS65894B1 (en) 2024-09-30
SG11201606269WA (en) 2016-09-29
JP2023087046A (en) 2023-06-22
CN106458986B (en) 2019-01-04
WO2015118342A8 (en) 2016-06-30
HK1231473A1 (en) 2017-12-22
ES2688548T3 (en) 2018-11-05
JP2021006571A (en) 2021-01-21
RU2016133684A3 (en) 2018-08-31
PT3406609T (en) 2024-09-17

Similar Documents

Publication Publication Date Title
FI3406609T3 (en) Bicyclic aza compounds as muscarinic receptor agonists
CL2015000578A1 (en) Compound n- (2- (6-fluoro-1-h-indol-3-yl) ethyl) -3- (2,2,3,3-tetrafluoropropoxy) benzylamine or its salt, 5-ht6 receptor antagonist; pharmaceutical composition; Use in the treatment of Alzheimer's disease.
PH12016501355A1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
MX2014004479A (en) Novel oxazine derivatives and their use in the treatment of disease.
MY196243A (en) Dihydropyrimidine Compounds and Their Application In Pharmaceuticals
IN2012DN02968A (en)
BR112012027743A2 (en) cyclopropyl dicarboxamides and analogs exhibiting anticancer and antiproliferative activities
MX2018003215A (en) Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors.
MX2016006564A (en) Dihydropyrimidine compounds and their application in pharmaceuticals.
GT201400301A (en) 7H-PIRROLO [2,3-D] PYRIMIDINS-4- (AMINHO-SUBSTITUTES) NOVELTY AS INHIBITORS OF LRRK2
MY182403A (en) Dihydropyrimidine compounds and their application in pharmaceuticals
JO3146B1 (en) Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders
BR112014028395A2 (en) substituted 3,4-dihydro-2h-pyrido [1,2-a] pyrazine-1,6-dione derivatives useful for the treatment of (inter alia) alzheimer's disease
JP2015501783A5 (en)
PH12017500111A1 (en) Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
BR112018003489A2 (en) n- [2- (2-amino-6,6-disubstituted-4,4a, 5,6-tetrahydropyran [3,4-d] [1,3] thiazin-8a (8h) -yl) -1 1,3-thiazol-4-yl] amides
UA117154C2 (en) S1p3 antagonists
PH12015500012A1 (en) Benzodioxole derivative and preparation method and use thereof
EP2676665A4 (en) USE OF MANGOSTINE- IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
PH12015502676A1 (en) 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1h-pyrrol-3-yl)benzenesulfonamide as alpha 7 nachr modulator
WO2014014794A3 (en) Mineralocorticoid receptor antagonists
WO2014163622A8 (en) Multifunctional quinoline derivatives as anti-neurodegenerative agents
NZ747778A (en) Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist
NZ747797A (en) Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist
MX2017013694A (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer's disease.